Tirzepatide achieves major weight loss and diabetes prevention, while Eli Lilly adjusts earnings guidance amid inventory issues.
Sectors & Industries
November 6, 2024
In a three-year study, tirzepatide—sold as Zepbound and Mounjaro—led to an average 22.9% reduction in body weight for adults with pre-diabetes and obesity on the highest dose. The drug also reduced the risk of developing type 2 diabetes by 94% compared to a placebo.
Tirzepatide mimics two gut hormones, GLP-1 and GIP, which regulate appetite and glucose. While on the drug, patients maintained lower body weight and slowed diabetes progression. Some weight regain was observed after stopping treatment. Common side effects included mild nausea and constipation.
Eli Lilly’s recent earnings report missed forecasts, and the company lowered its guidance due to inventory issues with Mounjaro and Zepbound. Revenue rose 20% to $11.44 billion, but the earnings-per-share outlook was adjusted to between $13.02 and $13.52.
.png)
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better trader.